Science
The obesity market is experiencing the most explosive growth in modern pharmaceutical history. With the rise of GLP-1 medications and a flood of semaglutide generics entering the market, the landscape is shifting from clinical discovery to a massive battle for market access and positioning.
In this episode of Game of Pharma, Lokesh sits down with Dr. Evan Nadler to decode the reality of this multi-billion-dollar therapeutic gold rush. We move past the consumer hype and break down the commercial realities of metabolic treatments.
In this episode, we cover:
- The GLP-1 Gold Rush: How the massive surge in obesity therapeutics is fundamentally changing pharmaceutical brand strategy.
- The Access Gap: Why the gap in treatment access is the single biggest opportunity (and hurdle) in healthcare right now.
- US vs. India: Comparing the structural differences between the US and Indian markets regarding metabolic therapies.
- Semaglutide Positioning: How pharma companies must position their branded generics to win the long game in a highly saturated market.
Whether you are a pharma marketer, brand manager, or healthcare executive, this conversation provides a strategic roadmap for navigating the biggest market shift in a generation.
#PharmaStrategy #GLP1 #ObesityMarket #PharmaMarketing #HealthcareInnovation #GameOfPharma #Semaglutide #BestPharmaPodcast
Dr. Nadler's LinkedIn: https://www.linkedin.com/in/evanpnadler/
Host's LinkedIn: https://www.linkedin.com/in/lokesh-sharma-7250a71a9/
Follow us on social media-
Website: https://gameofpharma.com/
Instagram: https://www.instagram.com/gameofpharma/